Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

East Hanover, New Jersey 07936


Purpose:

Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the long term safety and effectiveness of vildagliptin, an unapproved drug, compared to that of glimepiride in lowering overall blood glucose levels when added to metformin in people with type 2 diabetes not at target blood glucose levels on metformin alone.


Criteria:

Inclusion Criteria: - On a stable dose of metformin as defined by the protocol - Body mass index (BMI) in the range 22-45 - Blood glucose criteria must be met Exclusion Criteria: - Pregnancy or lactation - Type 1 diabetes - Evidence of significant diabetic complications - Evidence of serious cardiovascular complications - Laboratory value abnormalities as defined by the protocol - Other protocol-defined exclusion criteria may apply


NCT ID:

NCT00106340


Primary Contact:

Study Director
Novartis Pharmaceuticals
Novartis Pharmaceuticals


Backup Contact:

N/A


Location Contact:

East Hanover, New Jersey 07936
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 11, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.